Corning led the basket on a multibillion-dollar AT&T fiber deal unrelated to its pharma-glass franchise, while bioprocessing and life-science tools sold off with Maravai and Repligen hit hardest.

Corning (GLW) was the largest gainer, up 6.0% to $168.97, but honesty requires flagging that the catalyst sits outside this vertical's chokepoint: the move came on a new $3B-plus AT&T optical-fiber agreement and a UBS price-target raise to $201, driven by AI and broadband demand for high-density fiber — not its pharmaceutical glass & vials franchise. In pharma, Corning owns the vial chokepoint through its Valor and Velocity borosilicate lines; on Tuesday it traded entirely as an optical-networking name, which is why a glass maker tops a pharma basket on fiber news.

The laggard was Maravai LifeSciences (MRVI), down 7.9% to $7.85, with Repligen (RGEN) −7.7% to $174.86 — the bioprocessing consumables & resins and peptide/oligonucleotide-manufacturing chokepoints sold off as a group on no fresh positive catalyst, the same risk-off tone that knocked Bruker −5.3% in the quantum basket. Maravai supplies nucleic-acid raw materials for mRNA; Repligen fell the day it closed its BioLife Solutions acquisition, the dilution and cash outlay weighing. Thermo Fisher (TMO) −3.0% to $656.58 and Danaher (DHR) −2.5% rounded out the analytical-instruments weakness.

Elsewhere the tape was mixed to firm. The CDMO capacity & China-exodus rung held up — WuXi AppTec's ADR (WUXAY) +1.8% and Siegfried's ADR (SOAGY) +3.5% — while Eli Lilly (LLY) rose 1.3% to $1,157.49. The drug-contact-components rung was soft, with West Pharmaceutical (WST) −1.1% and Charles River (CRL) −1.9%, leaving the session a story of one idiosyncratic fiber-driven leader against a broad-based tools and consumables pullback.

The calendar is live. CPhI Worldwide (Milan, Oct 6–8) is underway — the year's key CDMO and supply-chain gathering, where fill-finish and API-reshoring capacity gets contracted. West Pharmaceutical reports Q3 on October 22 and Charles River around November 5. The structural overhang remains the BIOSECURE Act: the OMB's initial list of biotechnology "companies of concern" is due December 18, the dated trigger the China-exodus thesis trades against.